Treasurer of the State of North Carolina Has $2.75 Million Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)

Treasurer of the State of North Carolina lessened its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 3.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,344 shares of the medical research company’s stock after selling 758 shares during the period. Treasurer of the State of North Carolina’s holdings in Charles River Laboratories Intl. were worth $2,745,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CRL. Bank of New York Mellon Corp grew its position in shares of Charles River Laboratories Intl. by 49.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock worth $138,804,000 after purchasing an additional 323,625 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Charles River Laboratories Intl. by 18.0% during the 1st quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock worth $301,042,000 after purchasing an additional 317,001 shares in the last quarter. King Luther Capital Management Corp lifted its holdings in shares of Charles River Laboratories Intl. by 179.0% during the 2nd quarter. King Luther Capital Management Corp now owns 343,777 shares of the medical research company’s stock worth $48,782,000 after acquiring an additional 220,562 shares during the period. Nuveen Asset Management LLC lifted its holdings in shares of Charles River Laboratories Intl. by 3,703.6% during the 2nd quarter. Nuveen Asset Management LLC now owns 203,189 shares of the medical research company’s stock worth $28,832,000 after acquiring an additional 197,847 shares during the period. Finally, Trinity Street Asset Management LLP bought a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter worth approximately $20,486,000. Hedge funds and other institutional investors own 94.31% of the company’s stock.

CRL has been the subject of a number of recent analyst reports. SunTrust Banks upped their price target on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, September 16th. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Credit Suisse Group set a $138.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Friday, September 13th. Finally, Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, September 30th. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $149.69.

In other news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the transaction, the insider now owns 19,327 shares of the company’s stock, valued at $2,519,467.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.80% of the stock is currently owned by company insiders.

CRL stock opened at $129.48 on Wednesday. The company has a fifty day moving average price of $131.89 and a 200-day moving average price of $135.16. The company has a market capitalization of $6.43 billion, a P/E ratio of 21.47, a PEG ratio of 1.68 and a beta of 1.09. Charles River Laboratories Intl. Inc has a 52-week low of $103.00 and a 52-week high of $149.07. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.55 by $0.08. The firm had revenue of $657.60 million during the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.62 earnings per share. As a group, sell-side analysts forecast that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current fiscal year.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Buyback For Investors Defined

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.